Genentech this morning announced that it has halted enrolling patients in a study testing its Avastin, which is widely forecast to become the best-selling cancer drug ever, in advanced ovarian cancer.

FORBES: Magazine Article

Genentech (nyse: DNA - news - people ) this morning announced that it has halted enrolling patients in a study testing its Avastin, which is widely forecast to become the best-selling cancer drug ever, in advanced ovarian cancer.

FORBES: Avastin Sales Could Still Hit $7 Billion Per Year

Terence Flynn an analyst at Lazard Capital Markets, forecast in a note to investors that there was an 85% chance this study would fail.

FORBES: Health Care

Separately, a study by the Reuters news agency shows that, if the current cold snap continues as forecast, the country could run out of stored gas supplies as soon as 8 April.

BBC: SSE boss Ian Marchant warns of risk of 'lights going out'